Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies

被引:253
作者
Dodson, Shontelle [1 ]
Baracos, Vickie E. [2 ]
Jatoi, Aminah [3 ]
Evans, William J. [4 ]
Cella, David [5 ]
Dalton, James T. [1 ]
Steiner, Mitchell S. [1 ]
机构
[1] GTx Inc, Memphis, TN 38103 USA
[2] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[3] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[4] GlaxoSmithKline, Muscle Metab Discovery Performance Unit, Res Triangle Pk, NC 27709 USA
[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 | 2011年 / 62卷
关键词
anabolic; body composition; sarcopenia; selective androgen receptor modulator; skeletal muscle metabolism; quality of life; ANDROGEN RECEPTOR MODULATORS; SKELETAL-MUSCLE; BODY-COMPOSITION; MEGESTROL-ACETATE; SARCOPENIC OBESITY; SIGNALING PATHWAYS; WEIGHT-LOSS; CHEMOTHERAPY; PREVALENCE; MECHANISMS;
D O I
10.1146/annurev-med-061509-131248
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Cancer cachexia is a complex metabolic condition characterized by loss of skeletal muscle. Common clinical manifestations include muscle wasting, anemia, reduced caloric intake, and altered immune function, which contribute to increased disability, fatigue, diminished quality of life, and reduced survival. The prevalence of cachexia and the impact of this disorder on the patient and family underscore the need for effective management strategies. Dietary supplementation and appetite stimulation alone are inadequate to reverse the underlying metabolic abnormalities of cancer cachexia and have limited long-term impact on patient quality of life and survival. Therapies that can increase muscle mass and physical performance may be a promising option; however, there are currently no drugs approved for the prevention or treatment of cancer cachexia. Several agents are in clinical development, including anabolic agents, such as selective androgen receptor modulators and drugs targeting inflammatory cytokines that promote skeletal muscle catabolism.
引用
收藏
页码:265 / 279
页数:15
相关论文
共 85 条
[1]
[Anonymous], J CLIN ONCOL
[2]
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma [J].
Antoun, S. ;
Baracos, V. E. ;
Birdsell, L. ;
Escudier, B. ;
Sawyer, M. B. .
ANNALS OF ONCOLOGY, 2010, 21 (08) :1594-1598
[3]
Molecular mechanisms involved in muscle wasting in cancer and ageing:: cachexia versus sarcopenia [J].
Argilés, JM ;
Busquets, S ;
Felipe, A ;
López-Soriano, FJ .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (05) :1084-1104
[4]
Aslani A, 2000, CANCER-AM CANCER SOC, V88, P796, DOI 10.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO
[5]
2-P
[6]
MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis [J].
Attaix, Didier ;
Baracos, Vickie E. .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2010, 13 (03) :223-224
[7]
Baracos VE, 2001, CANCER, V92, P1669, DOI 10.1002/1097-0142(20010915)92:6+<1669::AID-CNCR1495>3.0.CO
[8]
2-S
[9]
Cancer-associated cachexia and underlying biological mechanisms [J].
Baracos, Vickie E. .
ANNUAL REVIEW OF NUTRITION, 2006, 26 :435-461
[10]
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis [J].
Baracos, Vickie E. ;
Reiman, Tony ;
Mourtzakis, Marina ;
Gioulbasanis, Ioannis ;
Antoun, Sami .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (04) :1133S-1137S